Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:10/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of dirucotide (MBP8298) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the sixth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of dirucotide (MBP8298) in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of dirucotide (MBP8298) versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... CARDIFF, UK (PRWEB) , ... December 08, 2016 ... ... high precision light to control cells — optogenetics — is key to exciting ... state of the art, spatially patterned light projected via free-space optics stimulates small, ...
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... Frederick, Maryland (PRWEB) , ... ... ... Inc announces the commercial launch of flexible packaging for their exceptionally ... (“SU”) disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
Breaking Biology Technology:
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
Breaking Biology News(10 mins):